COLLABORATIVE DEVELOPMENT AND COMMERCIALIZATION AGREEMENTCollaborative Development and Commercialization Agreement • November 3rd, 2021 • Tracon Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • New York
This Collaborative Development and Commercialization Agreement (the “Agreement”) is entered into on October 8, 2021 (the “Effective Date”) between Tracon Pharmaceuticals, Inc., a Delaware corporation, with its principal place of business at 4350 La Jolla Village Drive, Suite 800, San Diego, CA, USA (“Tracon”), Eucure (Beijing) Biopharma Co., Ltd., a company organized and existing under the laws of the People’s Republic of China and having its registered address at 23F, Tower 3, China Central Place, No.77, Jian Guo Road, Chaoyang District, Beijing, China (“Eucure”), and, solely with respect to Section 13.15, Eucure’s controlling Affiliate Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a company organized and existing under the laws of the People’s Republic of China and having its registered address at No.12, Baoshen South Street, Daxing Bio-Medicine Industry Park, 102600 Daxing District, Beijing, China (“Parent”). Eucure and Tracon are sometimes referred to herein individually as a “Pa
